GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald ...

After flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, ...

A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and ...